Eric H. Rubin

机构：American Association For Cancer Research · ORCID：0000-0002-8032-7913

发表论文 237 篇 · 总被引 11188 次 · h-index 59

代表论文

• Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020 · Journal for ImmunoTherapy of Cancer · 被引 294)
• Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors (2022 · Journal for ImmunoTherapy of Cancer · 被引 166)
• A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer (2020 · Clinical Cancer Research · 被引 126)
• Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology (2018 · JNCI Journal of the National Cancer Institute · 被引 94)
• Challenges to Using Big Data in Cancer (2023 · Cancer Research · 被引 66)
• Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials (2022 · JAMA Oncology · 被引 51)